MALI
MALI Platform
AI Stock Research

RA Capital Management, L.P.: latest 13F holdings

For the quarter ending 30 September 2026, RA Capital Management, L.P. reported 92 positions worth $10.0B in total, filed with the SEC on 16 November 2026. The quarter before, it reported $11.5B.

Read the filing at SEC EDGAR
Checked: the cover page's entry count and total value match the holdings table.

Top 50 positions by value

#IssuerClassValueWeightSharesvs quarter before
1ASCENDIS PHARMA A/SCommon Stock$2.3B23.50%10,281,496Unchanged
2PARABILIS MEDICINES INCCommon Stock$942.2M9.45%29,177,964Added 0.8%
3VAXCYTE INCCommon Stock$652.9M6.55%11,474,599Unchanged
4RHYTHM PHARMACEUTICALS INCCommon Stock$634.8M6.37%6,666,837Unchanged
5EDGEWISE THERAPEUTICS INCCommon Stock$340.7M3.42%8,392,730Unchanged
6TYRA BIOSCIENCES INCCommon Stock$266.8M2.68%12,198,625Unchanged
7FREENOME INCCommon Stock$242.0M2.43%15,367,270New
8HEMAB THERAPEUTICS HOLDINGSCommon Stock$240.8M2.42%7,808,627Unchanged
9NEWAMSTERDAM PHARMA CO NVCommon Stock$232.3M2.33%9,550,191Unchanged
10SEPTERNA INCCommon Stock$215.3M2.16%5,502,858Cut 21.3%
11SPYGLASS PHARMA INCCommon Stock$208.5M2.09%8,021,117Unchanged
12JANUX THERAPEUTICS INCCommon Stock$193.4M1.94%11,189,693Unchanged
13MINERALYS THERAPEUTICS INCCommon Stock$193.3M1.94%7,692,750Unchanged
14DISC MEDICINE INCCommon Stock$160.4M1.61%2,450,221Unchanged
15TAYSHA GENE THERAPIES INCCommon Stock$148.2M1.49%30,435,190Added 29.2%
16BICARA THERAPEUTICS INCCommon Stock$135.0M1.35%7,255,993Unchanged
17ARTIVA BIOTHERAPEUTICS INCCommon Stock$131.6M1.32%18,489,293Added 3.0%
18XENCOR INCCommon Stock$131.6M1.32%5,274,274Unchanged
19ORUKA THERAPEUTICS INCCommon Stock$129.5M1.30%1,554,597Unchanged
20AMYLYX PHARMACEUTICALS INCCommon Stock$124.5M1.25%4,279,341New
21CLIMB BIO INCCommon Stock$116.2M1.17%10,130,130Cut 10.4%
22ABIVAX SA-ADRADR$102.0M1.02%1,030,058Cut 9.1%
23WAVE LIFE SCIENCES INCCommon Stock$99.8M1.00%26,975,505New
24LATIGO BIOTHERAPEUTICS INCCommon Stock$88.6M0.89%5,302,933New
25SOLID BIOSCIENCES INCCommon Stock$87.0M0.87%12,036,126Unchanged
26VOR BIOPHARMA INCCommon Stock$85.9M0.86%4,503,882Added 87.5%
27LB PHARMACEUTICALS INCCommon Stock$84.8M0.85%2,208,604Unchanged
28GH RESEARCH PLCCommon Stock$84.7M0.85%3,609,007Cut 52.7%
29OBSIDIAN THERAPEUTICS INCCommon Stock$81.8M0.82%5,957,103New
30ZAI LAB LTD-ADRADR$74.2M0.74%2,815,543Cut 51.0%
314D MOLECULAR THERAPEUTICS INCommon Stock$72.3M0.72%5,049,779Unchanged
32ACLARIS THERAPEUTICS INCCommon Stock$66.9M0.67%12,723,026Unchanged
33SANA BIOTECHNOLOGY INCCommon Stock$54.7M0.55%18,750,000Unchanged
34MONOPAR THERAPEUTICS INCCommon Stock$53.2M0.53%667,207Unchanged
35GERON CORPCommon Stock$52.6M0.53%42,754,145Cut 0.1%
36DAMORA THERAPEUTICS INCCommon Stock$51.1M0.51%2,399,702New
37PEPGEN INCCommon Stock$48.6M0.49%20,064,545Unchanged
38ARS PHARMACEUTICALS INCCommon Stock$46.8M0.47%10,860,977Unchanged
39ACUMEN PHARMACEUTICALS INCCommon Stock$46.6M0.47%20,992,669Unchanged
40DBV TECHNOLOGIES SA-SPON ADRCommon Stock$43.0M0.43%3,657,644New
41AGENUS INCCommon Stock$40.9M0.41%4,122,000New
42REZOLUTE INCCommon Stock$39.1M0.39%9,445,039Unchanged
43SIONNA THERAPEUTICS INCCommon Stock$34.0M0.34%6,456,234Cut 34.8%
44SCRIBE THERAPEUTICS INCCommon Stock$33.2M0.33%1,802,178New
45CENTURY THERAPEUTICS INCCommon Stock$30.4M0.30%17,754,430Unchanged
46EVOMMUNE INCCommon Stock$28.9M0.29%3,494,638Unchanged
47KORSANA BIOSCIENCES INCCommon Stock$28.6M0.29%892,743New
48CAPRICOR THERAPEUTICS INCCommon Stock$28.5M0.29%3,014,183Added 99.9%
49NKARTA INCCommon Stock$28.3M0.28%10,805,129Unchanged
50C4 THERAPEUTICS INCCommon Stock$27.3M0.27%8,194,779Added 2.4%

Showing the largest 50 of 92 positions. Every position is in MALI's SEC Financials & 13F workspace.

New this quarter

  • FREENOME INC · $242.0M
  • AMYLYX PHARMACEUTICALS INC · $124.5M
  • WAVE LIFE SCIENCES INC · $99.8M
  • LATIGO BIOTHERAPEUTICS INC · $88.6M
  • OBSIDIAN THERAPEUTICS INC · $81.8M
  • DAMORA THERAPEUTICS INC · $51.1M
  • DBV TECHNOLOGIES SA-SPON ADR · $43.0M
  • AGENUS INC · $40.9M
  • SCRIBE THERAPEUTICS INC · $33.2M
  • KORSANA BIOSCIENCES INC · $28.6M

Sold out

  • BIOCRYST PHARMACEUTICALS INC · was $158.3M
  • WAVE LIFE SCIENCES LTD · was $156.7M
  • NUVALENT INC-A · was $153.9M
  • INTELLIA THERAPEUTICS INC · was $76.6M
  • DEFINIUM THERAPEUTICS INC · was $70.6M
  • DAMORA THERAPEUTICS INC · was $62.4M
  • AKTIS ONCOLOGY INC · was $42.4M
  • BIOAGE LABS INC · was $41.0M
  • KARYOPHARM THERAPEUTICS INC · was $18.7M
  • WAYSTAR HOLDING CORP · was $10.9M

Reading a 13F

A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.

Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.

Other managers